Catalent in den Nachrichten
Partner für die Arzneimittelentwicklung und -herstellung
Tamtam hat 20 aktuelle Artikel über Catalent gefunden.
- Catalent launches ten-month gene-to-drug substance programme for complex biologics
- Catalent, Inc. Launches Accelerated Gene-To-Drug Substance Program For Complex Biologics In The U.S
- Catalent Launches Accelerated Gene-to-Drug Substance Program for Complex Molecules in the U.S.
- Catalent Launches Accelerated Gene-to-Drug Substance Program in US for Complex Biologics
- ALK-Abelló (CPSE:ALK B) Expands Catalent Deal, Is The 32% Undervaluation Case Convincing?
- ALK expands Catalent partnership: what it means for Catalent stock
- ALK expands strategic tablet supply partnership with Catalent
- ALK expands Catalent partnership – guidance is maintained
- ALK Expands Tablet Supply Partnership With Catalent
- ALK, Catalent Expand Long-Term Contract Manufacturing Collaboration
- ALK expands strategic tablet supply partnership with Catalent
- Catalent stock reports USD 4.7 billion refinancing
- Catalent stock holds near its yearly low as earnings lag
- Catalent stock gains after FDA clears key manufacturing site
- Catalent stock holds steady as investors await fresh earnings and guidance
- Catalent lands $4.1B debt deal to expand biologics and oral drug capacity
- Catalent uses AI on Azure to strengthen quality management system processes
- Catalent Completes $4.1 Billion Debt Refinancing To Cut Annual Interest Expense By $100 Million
- Scholar Rock drops Catalent facility from marketing application for muscle weakness drug
- Catalent Completes Successful Debt Refinancing
Von Tamtam gesammelte Artikel, die sich auf das Unternehmen beziehen, die neuesten zuerst. Jeder verlinkt auf seine Quelle.
Sie verkaufen an Unternehmen wie Catalent?
Tamtam findet die Unternehmen, die zu Ihrem idealen Kunden passen, recherchiert jeden Account und sagt Ihnen, wen Sie wann kontaktieren sollten.
Ähnliche Unternehmen finden